Marksans Pharma yesterday said its subsidiary has received market authorisation from the UK health regulator for its anti-diarrhoea medication Loperamide capsules. The UK MHRA has granted market authorisation to the company’s wholly-owned subsidiary Relonchem for Loperamide hard capsules (2mg), Marksans Pharma said in a regulatory filing.
It also said that it will manufacture the product at its Goa-based oral dosage facility.